<NewDataSet>
  <product>
    <productid>10259</productid>
    <categoryid>30</categoryid>
    <categoryname>Newsletters</categoryname>
    <productname>hcc acquires two ANDAs from Teva, strengthens its US portfolio</productname>
    <createdby>Kartik.jasani@hcccadila.com</createdby>
    <createdon>2016-09-16T06:57:10.133+05:30</createdon>
    <shortdescription>&lt;p&gt;&lt;a href="http://hcccadila.com/wp-content/uploads/2016/06/hcc-acquires-2-ANDAs-from-Teva.pdf" target="_blank" data-saferedirecturl="https://www.google.com/url?hl=en-GB&amp;amp;q=http://hcccadila.com/wp-content/uploads/2016/06/hcc-acquires-2-ANDAs-from-Teva.pdf&amp;amp;source=gmail&amp;amp;ust=1474109260148000&amp;amp;usg=AFQjCNESf5qla-9zP_c_OM3gwsAaaNAILQ"&gt;&lt;strong&gt;&lt;span style="font-size: 10.0pt; font-family: 'Arial','sans-serif'; text-decoration: none;"&gt;hcc acquires two ANDAs from Teva, strengthens its US portfolio&lt;/span&gt;&lt;/strong&gt;&lt;/a&gt;&lt;/p&gt;</shortdescription>
    <startdate>2016-09-16T00:00:00+05:30</startdate>
    <enddate>2017-01-31T23:59:59+05:30</enddate>
    <filename>hcc-acquires-2-ANDAs-from-Teva.pdf</filename>
  </product>
  <product>
    <productid>10258</productid>
    <categoryid>30</categoryid>
    <categoryname>Newsletters</categoryname>
    <smallimage />
    <bigimage />
    <productname>Pool for Hepatitis C Medicine, daclatasvir</productname>
    <createdby>Kartik.jasani@hcccadila.com</createdby>
    <createdon>2016-09-16T06:54:35.38+05:30</createdon>
    <shortdescription>&lt;p&gt;&lt;a href="http://hcccadila.com/wp-content/uploads/2016/07/hcc-to-produce-Daclatasvir-July-2016.pdf" target="_blank" data-saferedirecturl="https://www.google.com/url?hl=en-GB&amp;amp;q=http://hcccadila.com/wp-content/uploads/2016/07/hcc-to-produce-Daclatasvir-July-2016.pdf&amp;amp;source=gmail&amp;amp;ust=1474109260148000&amp;amp;usg=AFQjCNGnaN7RZvl9wf7hcpfK2AcNttxjkw"&gt;&lt;strong&gt;&lt;span style="font-size: 10.0pt; font-family: 'Arial','sans-serif'; text-decoration: none;"&gt;Pool for Hepatitis C Medicine, daclatasvir&lt;/span&gt;&lt;/strong&gt;&lt;/a&gt;&lt;/p&gt;</shortdescription>
    <startdate>2016-09-16T00:00:00+05:30</startdate>
    <enddate>2017-01-31T23:59:59+05:30</enddate>
    <videoembed />
    <filename>1hcc-to-produce-Daclatasvir-July-2016.pdf</filename>
  </product>
  <product>
    <productid>10257</productid>
    <categoryid>30</categoryid>
    <categoryname>Newsletters</categoryname>
    <productname>hcc enters into a sub-licensing agreement with The Medicines Patent </productname>
    <createdby>Kartik.jasani@hcccadila.com</createdby>
    <createdon>2016-09-16T06:48:37.3+05:30</createdon>
    <shortdescription>&lt;p&gt;&lt;a href="http://hcccadila.com/wp-content/uploads/2016/07/hcc-to-produce-Daclatasvir-July-2016.pdf" target="_blank" data-saferedirecturl="https://www.google.com/url?hl=en-GB&amp;amp;q=http://hcccadila.com/wp-content/uploads/2016/07/hcc-to-produce-Daclatasvir-July-2016.pdf&amp;amp;source=gmail&amp;amp;ust=1474109260148000&amp;amp;usg=AFQjCNGnaN7RZvl9wf7hcpfK2AcNttxjkw"&gt;&lt;strong&gt;&lt;span style="font-size: 10.0pt; font-family: 'Arial','sans-serif'; text-decoration: none;"&gt;hcc enters into a sub-licensing agreement with The Medicines Patent &lt;/span&gt;&lt;/strong&gt;&lt;/a&gt;&lt;/p&gt;</shortdescription>
    <startdate>2016-09-16T00:00:00+05:30</startdate>
    <enddate>2017-01-31T23:59:59+05:30</enddate>
    <filename>1hcc-to-produce-Daclatasvir-July-2016.pdf</filename>
  </product>
  <product>
    <productid>10255</productid>
    <categoryid>30</categoryid>
    <categoryname>Newsletters</categoryname>
    <productname>hcc receives final approval from the USFDA for Nateglinide Tablets USP</productname>
    <createdby>intranet@creativewebmall.com</createdby>
    <createdon>2016-09-16T06:14:15.657+05:30</createdon>
    <shortdescription>&lt;p&gt;&lt;a href="http://hcccadila.com/wp-content/uploads/2016/07/Nateglinide-Tablets.pdf" target="_blank" data-saferedirecturl="https://www.google.com/url?hl=en-GB&amp;amp;q=http://hcccadila.com/wp-content/uploads/2016/07/Nateglinide-Tablets.pdf&amp;amp;source=gmail&amp;amp;ust=1474109135168000&amp;amp;usg=AFQjCNE1r2I_UFAuIket3ZCuC7scQadeDQ"&gt;&lt;strong&gt;&lt;span style="font-size: 10.0pt; font-family: 'Arial','sans-serif'; text-decoration: none;"&gt;hcc receives final approval from the USFDA for Nateglinide Tablets USP&lt;/span&gt;&lt;/strong&gt;&lt;/a&gt;&lt;/p&gt;</shortdescription>
    <startdate>2016-09-16T00:00:00+05:30</startdate>
    <enddate>2017-01-31T23:59:59+05:30</enddate>
    <filename>Nateglinide-Tablets.pdf</filename>
  </product>
  <product>
    <productid>10254</productid>
    <categoryid>30</categoryid>
    <categoryname>Newsletters</categoryname>
    <productname>hcc strengthens its derma portfolio with the brand acquisition of MELGAIN from Issar Pharma.</productname>
    <createdby>intranet@creativewebmall.com</createdby>
    <createdon>2016-09-16T06:13:31.327+05:30</createdon>
    <shortdescription>&lt;p&gt;hcc strengthens its derma portfolio with the brand acquisition of MELGAIN from Issar Pharma in India.&lt;/p&gt;</shortdescription>
    <startdate>2016-09-16T00:00:00+05:30</startdate>
    <enddate>2017-01-31T23:59:59+05:30</enddate>
    <filename>melgain_press_release.pdf</filename>
  </product>
</NewDataSet>